Podofilox

Podofilox is a topical antimitotic agent used in the treatment of external genital and perianal warts (condylomata acuminata). It is supplied as a 0.5% topical solution or gel and is marketed under brand names such as Condylox. It is a derivative of the podophyllotoxin family and is intended for external use only.

Mechanism of action is through inhibition of tubulin polymerization, disrupting microtubule formation and causing mitotic arrest in treated cells. This local cytotoxic effect destroys wart tissue with minimal systemic absorption when used as directed.

Indications for podofilox include treatment of external genital warts in adults and adolescents. It is not approved for internal lesions, mucosal surfaces, or internal genital warts, and it should be used as directed by a healthcare provider or as patient-applied therapy when appropriate.

Administration and dosing guidelines commonly involve applying the medication to the affected warts two times daily for three days, followed by a four-day break. These cycles may be repeated for several weeks as needed. Apply only to the warts and avoid surrounding healthy skin; wash hands after application; avoid contact with eyes, mouth, or other mucous membranes. Do not cover the treated area unless instructed, and avoid use on large areas of skin. Pregnant individuals should avoid use unless specifically advised by a clinician.

Contraindications include hypersensitivity to podofilox or related compounds. It should not be used during pregnancy and caution is advised in nursing individuals. Patients with active dermatitis at the treatment site or those who experience severe local irritation should discontinue use and seek medical advice.

Common adverse effects are local irritation at the application site, including burning, itching, redness, erosion, or edema. Systemic toxicity is rare with proper topical use. Storage is at room temperature away from heat and out of reach of children.